Xencor XNCR
NASDAQ XNCR
$26.60 -0.02 (-0.08%)
As of: Sep 4, 2026 · 1:40 PM EDT

Xencor (XNCR) Non Operating Investment Income (2015 - 2026)

Xencor (XNCR) posted quarterly Non Operating Investment Income of -$51.9 million for Q1 2026, down 5618.49% year-over-year from $941000.0 in Q1 2025, and down 201.02% quarter-over-quarter from $51.4 million in Q4 2025.

Analysis

Xencor (XNCR) Non Operating Investment Income (2015 - 2026) Analysis & Trends

Xencor (XNCR) has reported Non Operating Investment Income for 12 consecutive years, with -$51.9 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Non Operating Investment Income fell 5618.49% year-over-year to -$51.9 million; the TTM figure through Mar 2026 stood at $48.6 million (up 248.28% YoY), while the FY2025 annual figure was $101.5 million, up 423.07% from the prior year.
  • Non Operating Investment Income fell to -$51.9 million in Q1 2026 per XNCR's latest filing, from $51.4 million in the prior quarter.
  • Across five years, Non Operating Investment Income topped out at $51.4 million in Q4 2025 and bottomed at -$51.9 million in Q1 2026.
  • Historically, Non Operating Investment Income has averaged $3.8 million across 5 years, with a median of $2.3 million in 2024.
  • Annual changes were most pronounced in 2022 — Non Operating Investment Income slumped 15008.7% — and 2024, when it jumped 671.17%.
  • Xencor's Non Operating Investment Income stood at $31.8 million in 2022, then sank by 58.37% to $13.2 million in 2023, then slumped by 333.98% to -$31.0 million in 2024, then jumped by 265.96% to $51.4 million in 2025, then sank by 201.02% to -$51.9 million in 2026.
  • Business Quant data shows XNCR's Non Operating Investment Income at -$51.9 million in Q1 2026, $51.4 million in Q4 2025, and $44.2 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Investment Income (Qtr)
1 Vertex Pharmaceuticals 139.31 Bn 131.46 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.65 Bn 77.66 Bn 3.93 Bn -
3 Argenx Se 63.46 Bn 58.27 Bn 1.37 Bn -
4 Moderna 57.94 Bn 52.80 Bn 52.00 Mn -
5 Revolution Medicines 44.05 Bn 44.05 Bn - -
6 BeOne Medicines 39.96 Bn 34.86 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.16 Bn 31.85 Bn 992.69 Mn -
8 Royalty Pharma 28.44 Bn 27.60 Bn - -
9 Insmed 27.32 Bn 26.16 Bn 358.27 Mn -
10 Xencor 2.02 Bn 1.64 Bn - 18.06 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 18.06 Mn
Mar 31, 2026 -51.93 Mn
Dec 31, 2025 51.41 Mn
Sep 30, 2025 44.20 Mn
Jun 30, 2025 4.97 Mn
Mar 31, 2025 941,000.00
Dec 31, 2024 -30.97 Mn
Sep 30, 2024 9.25 Mn
Jun 30, 2024 -12.03 Mn
Mar 31, 2024 2.33 Mn
Dec 31, 2023 13.24 Mn
Sep 30, 2023 -11.02 Mn
Jun 30, 2023 1.80 Mn
Mar 31, 2023 3.33 Mn
Dec 31, 2022 31.83 Mn
Sep 30, 2022 5.30 Mn
Jun 30, 2022 -6.55 Mn
Mar 31, 2022 -5.61 Mn
Dec 31, 2021 -18.22 Mn
Sep 30, 2021 900,000.00